David B Volkin

Dr. Volkin is the Ronald T. Borchardt Distinguished Professor of Pharmaceutical Chemistry, and co-founder of the Vaccine Analytics and Formulation Center (VAFC) at The University of Kansas. The VAFC focuses on translation of novel vaccine/biotherapeutic candidates into clinical trials and collaborates with a network of global partners including academia, biopharma companies, vaccine manufacturers, and non-profit organizations.

Dr. Volkin joined the KU faculty in 2010 after a 20-year industry career including R&D senior director positions at Merck and J&J. He led formulation and analytical groups that brought dozens of candidates into human clinical trials, including five vaccines and three monoclonal antibodies approved by regulatory agencies. He is co-author of ~220 scientific publications and co-inventor on 15 U.S. patents, including the stabilization and formulation of the commercial human papillomavirus (Gardasil™) and rotavirus (RotaTeq™) vaccines. Dr. Volkin graduated with B.A. in Chemistry from the UC-San Diego and earned a Ph.D. in Biochemical Engineering from MIT. He was awarded the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Award in Biotechnology in 2015.